Navigation Links
ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
Date:1/8/2009

ins "forward-looking statements" which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the transaction's anticipated completion and the progress of the companies' clinical stage and research programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on the companies' managements' current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, failure of Nuvelo's stockholders to approve an amendment to Nuvelo's certificate of incorporation to effect a reverse stock split, which is a necessary condition to completion of the proposed merger, the ability to complete the proposed merger in a timely fashion, the risk that Nuvelo's and ARCA's business operations will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the combined company's financial resources will be insufficient to meet the combined company's business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in the companies' clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended September 30, 2008 and subsequent
'/>"/>
SOURCE ARCA biopharma, Inc. and Nuvelo, Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma
2. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
3. Helix BioPharma Announces Q1 2009 Financial Results
4. McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries
5. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
6. XTL Biopharmaceuticals Implements Restructuring Plan
7. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
8. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
9. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
10. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
11. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of the ... report to their offering. This report analyzes ... Thousands by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , ... Latin America . Annual estimates and forecasts are provided for ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 ... to raise $200,000 to fund a corporate lab ... , This development is a critical component ... of care to the implementation of personalized medicine ... of practicing medicine. , Indiegogo contributions will support ...
(Date:8/19/2014)... August 19, 2014 Robin Williams’ passing ... can take on an individual. Symptoms range from ... expression, problems swallowing and severe depression. Parkinson’s disease ... off of dopamine producing neurons of the brain. ... disease that slowly and progressively gets worse, they look ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... ... software (OSS) in clinical trial electronic data capture and clinical data management. , ... Waltham, MA (PRWEB) January ... trial software, will gather on March 22nd, 2010 in Bethesda, Maryland (USA) for the ...
... ... over 24 years of experience to Professional Reprographics. , ... Irvine, California (PRWEB) January 7, 2010 -- Orange ... as President of Professional Reprographics. The naming of Cindy as President reflects Pro Repro’s ...
... , , , , SHENYANG, ... ), a leading biotechnology company focused on researching,developing, manufacturing ... it has submitted its application for a,registrational clinical trial ... Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme is an intravenous ...
Cached Biology Technology:OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Woman Owned Business President Makes Her Mark at Professional Reprographics 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4
(Date:8/19/2014)... must be made to decrease China,s increasing caesarean section ... in BJOG: An International Journal of Obstetrics and ... highest caesarean delivery rates in the world. Of 16 ... caesarean. Although the exact rate is not known, the ... reports total caesarean rates ranging from 36% to 58%. ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... be used in supermarkets to encourage healthier spending habits? ... answer that very question by tracking the purchasing records ... System to rate the nutritional value of foods for ... Lab,s David Just, PhD, and Brian Wansink PhD, author ... of over 150 Hannaford Supermarkets in the Northeastern United ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... advance into the vanishingly small realm of molecules and ... venerable optical microscope, after all. In fact, research at ... that a hybrid version of the optical microscope might ... 10 nanometers—a tiny fraction of the wavelength of visible ...
... simple drug, given to children with severe malaria before they ... researchers in this week's BMJ. , Every year over a ... fatalities occur outside hospital, especially in rural areas. For those ... within 24 hours of admission. , Conventional treatment, given by ...
... potential new drug that inhibits destructive cell signals that ... scientists showed they could block the growth of cultured ... , Their finding, reported in the March 22, 2005, ... is the first step toward developing a new class ...
Cached Biology News:Devising Nano Vision for an Optical Microscope 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 2Newly Discovered Compound Blocks Known Cancer-Causing Protein 3
... Physical Form: buffered aqueous solution. ... terminal galactose from complex carbohydrates and glycoproteins. ... galactose under conditions where the pH must ... live cells. Unit Definition: ...
... for human cardiac troponin subunit T, a 31kDa ... for contraction of cardiac muscle. It reacts with ... cells. It also cross-reacts with human skeletal troponin ... Highly purified human cardiac troponin T ...
cystatin A (N-18)...
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Biology Products: